Candel Therapeutics 第四季度每股收益 $(0.40) 未达预期值 $(0.23)

财报速递
14 Mar
Candel Therapeutics(股票代码:LENZ,纳斯达克:CADL)公布其季度每股亏损为 $(0.40),未达到分析师普遍预期的 $(0.23),相差73.91%。相比去年同期的每股亏损 $(0.38),下降了5.26%。

以上内容来自Benzinga Earnings专栏,原文如下:

Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.23) by 73.91 percent. This is a 5.26 percent decrease over losses of $(0.38) per share from the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10